Proteins > Voltage-dependent L-type calcium channel subunit alpha-1C
Page last updated: 2024-08-07 16:11:31
Voltage-dependent L-type calcium channel subunit alpha-1C
A voltage-dependent L-type calcium channel subunit alpha-1C that is encoded in the genome of rat. [OMA:P22002, PRO:DNx]
Synonyms
Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle;
Rat brain class C;
RBC;
Voltage-gated calcium channel subunit alpha Cav1.2
Research
Bioassay Publications (18)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 8 (44.44) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Compounds (29)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| gallopamil | Rattus norvegicus (Norway rat) | IC50 | 0.0230 | 1 | 1 |
| amlodipine | Rattus norvegicus (Norway rat) | Ki | 0.0020 | 1 | 1 |
| carbinoxamine | Rattus norvegicus (Norway rat) | Ki | 1.0800 | 1 | 1 |
| clotrimazole | Rattus norvegicus (Norway rat) | IC50 | 0.5900 | 1 | 1 |
| nicardipine | Rattus norvegicus (Norway rat) | IC50 | 24.1000 | 1 | 2 |
| nicardipine | Rattus norvegicus (Norway rat) | Ki | 0.0008 | 1 | 1 |
| nifedipine | Rattus norvegicus (Norway rat) | IC50 | 0.0385 | 2 | 2 |
| nifedipine | Rattus norvegicus (Norway rat) | Ki | 0.0038 | 2 | 4 |
| nisoldipine | Rattus norvegicus (Norway rat) | IC50 | 0.0030 | 1 | 1 |
| nitrendipine | Rattus norvegicus (Norway rat) | IC50 | 0.0013 | 1 | 1 |
| ondansetron | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 2 | 2 |
| propranolol | Rattus norvegicus (Norway rat) | IC50 | 21.0000 | 1 | 1 |
| dexpropranolol | Rattus norvegicus (Norway rat) | Ki | 14.5000 | 1 | 1 |
| diltiazem | Rattus norvegicus (Norway rat) | IC50 | 18.1376 | 4 | 5 |
| diltiazem | Rattus norvegicus (Norway rat) | Ki | 0.1323 | 3 | 3 |
| pinaverium | Rattus norvegicus (Norway rat) | IC50 | 1.7500 | 1 | 2 |
| besipirdine | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| ryodipine | Rattus norvegicus (Norway rat) | IC50 | 6,000,000.0000 | 1 | 2 |
| uk 68798 | Rattus norvegicus (Norway rat) | IC50 | 1,023.0000 | 1 | 1 |
| moxifloxacin | Rattus norvegicus (Norway rat) | IC50 | 238.7699 | 2 | 2 |
| solifenacin | Rattus norvegicus (Norway rat) | IC50 | 6.3096 | 1 | 1 |
| eplerenone | Rattus norvegicus (Norway rat) | IC50 | 5.0000 | 1 | 1 |
| curcumin | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| sitagliptin | Rattus norvegicus (Norway rat) | IC50 | 100,000.0000 | 1 | 1 |
| cilnidipine | Rattus norvegicus (Norway rat) | IC50 | 5.3000 | 1 | 3 |
| dexniguldipine | Rattus norvegicus (Norway rat) | Ki | 0.0597 | 1 | 1 |
| cilansetron | Rattus norvegicus (Norway rat) | Ki | 7.7000 | 2 | 2 |
| mebudipine | Rattus norvegicus (Norway rat) | IC50 | 0.0200 | 1 | 1 |
| nitd 609 | Rattus norvegicus (Norway rat) | IC50 | 10.0000 | 1 | 1 |
| sildenafil | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| XL413 | Rattus norvegicus (Norway rat) | IC50 | 28.4500 | 2 | 2 |
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| bay-k-8644 | Rattus norvegicus (Norway rat) | Concentration | 3.0000 | 1 | 1 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.Journal of applied toxicology : JAT, , Volume: 32, Issue:10, 2012
Stereoselectivity of a potent calcium antagonist, 1-benzyl-3-pyrrolidinyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate.Journal of medicinal chemistry, , Volume: 29, Issue:12, 1986
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.Journal of applied toxicology : JAT, , Volume: 32, Issue:10, 2012
A homologous series of permanently charged 1,4-dihydropyridines: novel probes designed to localize drug binding sites on ion channels.Journal of medicinal chemistry, , Nov-12, Volume: 36, Issue:23, 1993
Stereoselectivity of a potent calcium antagonist, 1-benzyl-3-pyrrolidinyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate.Journal of medicinal chemistry, , Volume: 29, Issue:12, 1986
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 23, Issue:6, 2013
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.Journal of applied toxicology : JAT, , Volume: 32, Issue:10, 2012
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: deBioorganic & medicinal chemistry, , Nov-01, Volume: 18, Issue:21, 2010
L-Type calcium channel blockers: from diltiazem to 1,2,4-oxadiazol-5-ones via thiazinooxadiazol-3-one derivatives.Journal of medicinal chemistry, , Apr-23, Volume: 52, Issue:8, 2009
Pyrrolo[2,1-c][1,4]benzothiazines: synthesis, structure-activity relationships, molecular modeling studies, and cardiovascular activity.Journal of medicinal chemistry, , Oct-27, Volume: 38, Issue:22, 1995